Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIGHT: High-Dose Gleevec in Newly Diagnosed CML
NCT00081926Phase 4Completed
- Sponsor
- Novartis
- Start
- Oct 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of imatinib in chronic myelogenous leukemia (CML), sponsored by Novartis. Primary endpoint: Major Molecular Response at 18 months. Started Oct 2003; status: completed.
02
Drugs
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT00081926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00081926.